Probabilistic cost-utility analysis and expected value of perfect information for the Oncotype multigenic test
A discrete event simulation model
Dados Bibliográficos
| ID | 21482295 |
|---|---|
| Autores | Oliver Ibarrondo (0000-0003-3310-719X, Hospital Alto Deba, autor correspondente), Isabel Álvarez (0000-0003-2016-0514, Biogipuzkoa Health Research Institute), Isabel Álvarez-López, Fred Freundlich (0000-0003-2697-5095, Mondragon Unibertsitatea), Frederick Freundlich, Arantzazu Arrospide (0000-0003-3537-6588, Osasun Sistemen Ikerketa Institutua), Elena Galve-Calvo, Elena Gálve (0000-0003-4204-5736, Hospital de Basurto), María Gutiérrez-Toribio (Hospital Universitario Araba), Arrate Plazaola (Onkologikoa), Javier Mar (0000-0002-9455-4869, Osasun Sistemen Ikerketa Institutua) |
| Ano | 2020 |
| Volume | 34 |
| Fascículo | 1 |
| Páginas | 61-68 |
| Data de publicação | 2020-01-01 |
| Peer Reviewed | Sim |
| Open Access | Sim |
| Tipo | ARTICLE |
| Periódico | Gaceta Sanitaria (JOURNAL) |
| Identificadores do periódico | ISSN: 0213-9111 • E-ISSN: 1578-1283 |
| Editora | Elsevier BV (PUBLISHER) |
| DOI | 10.1016/j.gaceta.2018.07.012 |
| PMID | 30442434 |
| OpenAlex | W2900493371 |
| Idioma | EN |
| Citações recebidas | 3 |
| Referências citadas | 26 |
To carry out a cost-utility analysis of the application of the Oncotype genomic test to inform the decision to use or not to use chemotherapy in the Basque Country (Spain). The cost-utility study was carried out using a discrete event simulation model representing the natural history of breast cancer. The decision of treatment with chemotherapy based on Oncotype was compared with the standard of treatment based on clinical-pathological criteria. The model included clinical data from Basque hospitals and the literature and was processed by deterministic and probabilistic analysis to calculate the incremental cost-effectiveness ratio (ICER), the cost-effectiveness plane, the acceptability curve and the expected value of perfect information. The study adopted both a health and societal perspective. From a health perspective, the deterministic analysis estimated an ICER for Oncotype of 17,453 euros/quality-adjusted life year (QALY), discount included, and 9,613 euros/QALY without the discount. Eighty five percent (85%) of the simulations were below the efficiency threshold for Spain. The parametric variability associated with the Oncotype results was the main uncertainty factor in the decision. Oncotype is a cost-effective intervention from a health system perspective since each QALY gained costs less than 25,000 euros. From a societal perspective, it is dominant since it provides greater health and is accompanied by cost savings. Llevar a cabo un análisis de coste-utilidad del uso del test genómico Oncotype en el País Vasco (España) para informar la decisión de uso de quimioterapia. El estudio de coste-utilidad se realizó mediante un modelo de simulación de eventos discretos que representó la evolución natural del cáncer de mama. La decisión de tratamiento con quimioterapia basada en Oncotype se comparó con el estándar de tratamiento basado en criterios clínico-patológicos. El modelo incluyó datos clínicos de hospitales vascos y la literatura para calcular la ratio de coste-efectividad incremental (RCEI) mediante análisis determinista y probabilístico, el plano coste-efectividad, la curva de aceptabilidad y el valor esperado de la información perfecta. El estudio adoptó una perspectiva tanto sanitaria como social. El análisis determinista estimó una RCEI para Oncotype de 17.453 euros/año de vida ajustado por calidad (AVAC) con descuento y 9613 euros euros/AVAC sin descuento, desde la perspectiva sanitaria. El 85% de las simulaciones estuvieron por debajo el umbral de aceptabilidad para España. La variabilidad paramétrica asociada a los resultados de Oncotype fue el mayor factor de incertidumbre de la decisión. Oncotype constituye una intervención coste-efectiva, ya que cada AVAC ganado tiene asociado un coste inferior a 25.000 euros. El test es dominante desde una perspectiva social al lograr mayor salud acompañada de ahorros
Cost effectiveness · Cost-effectiveness analysis · Cost–utility analysis · Euros · Gynecology · Humanities · Quality-adjusted life year · Statistics · BRCA gene mutations in cancer · Economic and Financial Impacts of Cancer · Health Systems, Economic Evaluations, Quality of Life · Mathematics · Medicine
| Obras citantes distintas | 3 |
|---|---|
| Citações por ano | 0,5 |
| Intervalo de citações | 2020 - 2025 (6) |
| Velocidade de citação | recent |
| Altamente citado | Não |
| Tipos de citação | Neutras: 2 |